Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Lorcan McGarvey"'
Autor:
Ulrich Bothner, Lorcan McGarvey, Gary T. Ferguson, Alan Hamilton, Sheldon Magder, Kay Tetzlaff, Claus Vogelmeier, Dennis E. Niewoehner, Paul Sachs, Andrea Koch, Lawrence Korducki
Publikováno v:
COPD
McGarvey, L, Niewoehner, D, Magder, S, Sachs, P, Tetzlaff, K, Hamilton, A, Korducki, L, Bothner, U, Vogelmeier, C, Koch, A & Ferguson, G T 2015, ' One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis ', COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 12, no. 5, pp. 484-493 . https://doi.org/10.3109/15412555.2014.991864
McGarvey, L, Niewoehner, D, Magder, S, Sachs, P, Tetzlaff, K, Hamilton, A, Korducki, L, Bothner, U, Vogelmeier, C, Koch, A & Ferguson, G T 2015, ' One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis ', COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 12, no. 5, pp. 484-493 . https://doi.org/10.3109/15412555.2014.991864
The novel long-acting β2-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies. This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT0078221